Fortrea (FTRE) vs. Its Rivals Head-To-Head Survey

Fortrea (NASDAQ:FTRE) is one of 43 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its competitors? We will compare Fortrea to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.

Valuation and Earnings

This table compares Fortrea and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Fortrea	$3.11 billion	-$3.40 million	-18.98
Fortrea Competitors	$1.05 billion	-$128.23 million	4.53

Fortrea has higher revenue and earnings than its competitors. Fortrea is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Fortrea and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortrea	-4.11%	4.76%	1.87%
Fortrea Competitors	-3,482.20%	-1,360.84%	-32.25%

Institutional & Insider Ownership

49.6% of shares of all “Medical laboratories” companies are owned by institutional investors. 0.1% of Fortrea shares are owned by company insiders. Comparatively, 19.3% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Fortrea and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1	2	5	1	2.67
Fortrea Competitors	307	1181	2036	33	2.50

Fortrea presently has a consensus price target of $35.57, suggesting a potential upside of 34.84%. As a group, “Medical laboratories” companies have a potential upside of 21.72%. Given Fortrea’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortrea is more favorable than its competitors.

Summary

Fortrea beats its competitors on 8 of the 12 factors compared.

About Fortrea

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.